Third study confirms value of PSADT as a prognostic indicator post-surgery
Posted Jan 19 2011 12:00am
Earlier studies based on data from Johns Hopkins and the Center for Prostate Disease Research have shown that PSA doubling times are strongly associated with risk for metastasis, prostate cancer-specific, and overall mortality.
A new study by Teeter et al. , based on the data from the SEARCH database, has now confirmed these findings in an older, racially diverse cohort of men treated by radical prostatectomy (RP) at a group of Veterans Affairs medical centers.
This newly published study reports on data from 345 men in the SEARCH database who underwent an RP between1988 and 2008. The authors looked specifically at the association between PSADT at initial recurrence and the time from recurrence to overall and prostate cancer-specific mortality using the clinically significant PSADT cutpoints of < 3.0, 3.0 to 8.9, 9.0 to 14.9, and ≥ 15.0 months.
Teeter et al. were able to show that, in this patient cohort, compared to a PSADT of ≥15 months:
Men with a PSADT of < 3 months had a poorer overall survival (hazard ratio [HR] = 5.48, P = 0.002).
Men with a PSADT of 3.0 to 8.9 months showed a trend toward poorer overall survival (HR = 1.70, P = 0.07).
PSADTs of < 3 months (P < 0.001) and 3.0 to 8.9 months (P = 0.004) were associated with an increased risk of prostate cancer-specific mortality.
PSADT is clearly a valuable prognostic tool for identifying men at increased risk of all-cause and prostate cancer-specific mortality early in their disease course.